A Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

NCT07547761 | Completed DMC

• 1 other identifier: NOBO105A03
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is: Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla to the placebo axilla to see if there is a difference in self-perceived odor and microbiome. Participants will:

• be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla)
• self assess body odor
• sample axilla with cotton round for 3rd party odor assessment
• sample axilla with a swab for skin microbiome analysis via qPCR
• self assess skin irritation

Conditions

Body Odor

Keywords

Body Odor; Deodorant

Outcome Measures

Primary Outcomes (1)

• Axillary odor self assessment (on 0-5 odor scale)

  A 0 on the odor scale corresponds to "no axillary odor"; a 5 corresponds to "very strong axillary odor"

  At baseline (before application), immediately after first application, Day 1 PM, Day 2 AM, and Day 2 PM; then once a day (PM) for Days 3-12

Secondary Outcomes (5)

• Axillary odor self assessment (comparative)

  At baseline (before application), immediately after first application, Day 1 PM, Day 2 AM, and Day 2 PM; then once a day (PM) for Days 3-12

• Axillary odor third party assessment (on 0-5 scale)

  At Day 2 AM, Day 6 AM, and Day 12 AM

• Axillary odor third party assessment (comparative)

  At Day 2 AM, Day 6 AM, and Day 12 AM

• Skin irritation (pain & redness) self assessment (0-4 Draize scale; 0-10 pain scale)

  At baseline (before application), Day 3 PM, Day 6 PM, Day 9 PM, Day 12 PM

• Axillary skin microbiome assessment via swab (qPCR to assess change in Staphylococcus genus)

  At baseline (Day 1 AM), Day 3 AM, Day 6 AM, Day 9 AM, and Day 12 AM

Study Arms (2)

NOBO aqueous deodorant

EXPERIMENTAL

The NOBO aqueous deodorant is composed of ≤7.2% yeast fermentation product (INCI: Yeast) and ≤ 40% ethanol in water. A dose is 0.48 mL per axilla for female subjects (3 actuations) or 0.64 mL per axilla for male subjects (4 actuations), delivered twice a day.

Other: NOBO Aqueous Deodorant

Placebo aqueous deodorant

PLACEBO COMPARATOR

The placebo deodorant is composed of ≤ 40% ethanol in water. The placebo deodorant contains the same concentration of ethanol as the NOBO aqueous deodorant. A dose is 0.48 mL per axilla for female subjects (3 actuations) or 0.64 mL per axilla for male subjects (4 actuations), delivered twice a day.

Other: Placebo Aqueous Deodorant

Interventions

NOBO Aqueous Deodorant OTHER

The active ingredient in the NOBO aqueous deodorant is a yeast-based fermentation product (postbiotic) of the Starmerella genus.

NOBO aqueous deodorant

Placebo Aqueous Deodorant OTHER

The placebo deodorant is composed of ≤ 40% ethanol in water.

Placebo aqueous deodorant

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: The subject is an adult between 18 and 70 y.o.
• Skin health: The subject has no active skin conditions or lesions in the axillary region and no existing skin conditions (e.g., eczema, psoriasis, contact dermatitis).
• Skin allergies: The subject has no known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs.

You may not qualify if:

• Subject is pregnant, nursing, or planning to become pregnant in the next 6 months.
• Subject is an insulin-dependent diabetic.
• Subject has been diagnosed or treated for cancer in the past 5 years.
• Subject is currently using or has not used in the past two weeks any systemic antibiotics.
• Subject is currently using or used within the last month any topical medications, over-the-counter (OTC) or prescription products on the underarms.
• Subject is currently taking or plans to take during the study any anti-inflammatory for a chronic condition (except 81 mg-Aspirin per day), immunosuppressant, antihistamine, or sedative medications (i.e. containing antihistamines like Tylenol PM, Nyquil, etc.).
• Subject is currently participating in another underarm clinical trial. Subjects may participate in other studies as long as the same test sites are not used or are testing similar products.

Sponsors & Collaborators

• Kingdom: lead

Study Sites (1)

Kingdom

Brooklyn, New York, 11205, United States

Location

MeSH Terms

Conditions

Body Odor

Condition Hierarchy (Ancestors)

Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Aylesse Sordillo, PhD

  Principal Scientist at Kingdom

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Split-axilla design: one axilla received intervention, other axilla receives placebo

Study Record Dates

• First Submitted: April 17, 2026
• First Posted: April 23, 2026
• Study Start: April 16, 2026
• Primary Completion: May 4, 2026
• Study Completion: May 4, 2026
• Last Updated: May 11, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)